Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commencement of dealings

19 Sep 2006 07:02

Quintessentially English PLC19 September 2006 QUINTESSENTIALLY ENGLISH PLC ("QE" OR THE "COMPANY") COMMENCEMENT OF DEALINGS Quintessentially English PLC (to be re-named Omega Diagnostics Group PLC)announces that it has completed inter alia the acquisition of Omega DiagnosticsLimited, a £1 million placing of new ordinary shares and an issue of warrants toexisting shareholders in the Company. Its ordinary shares are due to bereadmitted to trading on AIM today. Highlights • Acquisition of Omega Diagnostics Limited, a UK company specialising in in-vitro diagnostics test kits and related products through a distribution network in more than 100 countries • £1 million new equity (before expenses) raised via a cash placing of 50,000,000 New Ordinary Shares at 2p per share • Issue of 5,588,432 QE Warrants to existing Shareholders to subscribe for Ordinary Shares at an exercise price of 2p per share • Appointment of a new management team from Omega Diagnostics Limited: Andrew Shepherd, Chief Executive, Kieron Harbinson, Finance Director, David Evans, Non-executive Chairman; Michael Gurner continues as a Non-executive Director • The Acquisition furthers Omega's strategy to become a leading in-vitro diagnostics company - its strategy is to grow through selective acquisitions Andrew Shepherd, Chief Executive, commented: "The purchase of Omega Diagnostics Limited continues our aim to acquirecompanies within the medical diagnostics sector and positions us as a key playerin the in-vitro diagnostics kit market. Our strategy is to grow by acquisitionand to build our portfolio of products which we are already distributingthroughout the UK and in over 100 countries worldwide." On completion, the Company will be paying a maximum consideration of £3 millionof which approximately £1.2 million will be satisfied by the issue of 60,600,000 New Ordinary Shares and the balance of up to approximately £1.8 million as deferred consideration to be satisfied by way of up to 89,400,000 Earn Out Shares at a minimum issue price of 2p per share subject to certain earn out targets being met for the financial year ending 31 March 2008. Immediately following admission, the issued share capital of the Company will be 121,776,865 Ordinary Shares. For further information, please contact: Quintessentially English PLC (to be re-named Omega Diagnostics Group PLC) - 01259 763 030 Andrew ShepherdChief Executive Kieron HarbinsonFinance Director City Financial Associates Limited - 020 7090 7800 Barry SaintDirector END This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Apr 20187:00 amRNSStrategic Review of operations and Trading Update
12th Jan 201812:14 pmRNSHolding(s) in Company
21st Dec 20177:00 amRNSAllersys® CE-Mark
14th Dec 20177:01 amRNSCEO succession
14th Dec 20177:00 amRNSInterim results
29th Nov 20177:00 amRNSVISITECT® CD4 CE-Mark
1st Nov 20177:00 amRNSChange of Registered Office
23rd Oct 20177:00 amRNSTrading Update and Notice of Interim Results
18th Oct 20179:00 amRNSPDMR Participation in SAYE Scheme
16th Oct 20177:00 amRNSUS Supply Agreement
10th Oct 20177:00 amRNSHolding(s) in Company
5th Sep 20172:07 pmRNSExercise of Options and Total Voting Rights
29th Aug 201711:51 amRNSResult of AGM
18th Jul 201710:35 amRNSResult of General Meeting
6th Jul 201711:56 amRNSSale and leaseback of building owned by Omega GmbH
30th Jun 201712:13 pmRNSResult of Proposed Fundraising
30th Jun 20177:01 amRNSProposed Fundraising
30th Jun 20177:00 amRNSFinal Results
25th Apr 20177:00 amRNSTrading Update and Notice of Results
21st Apr 201712:41 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSVISITECT® Malaria CE-Mark & Indian FDA inspection
7th Mar 20178:45 amRNSHolding(s) in Company
27th Feb 201712:52 pmRNSHolding(s) in Company
27th Jan 20177:00 amRNSUpdate on discussions with IDS
11th Jan 20177:00 amRNSISO accreditation for manufacturing facility
29th Nov 20167:15 amRNSHardman Research: Food intolerance driving growth
24th Nov 20167:52 amRNSHolding(s) in Company
21st Nov 20167:00 amRNSHalf-year Report
31st Oct 20167:15 amRNSHardman Research: Diagnosing growth opportunities
17th Oct 20167:00 amRNSTrading Update and Notice of Interim Results
10th Aug 201612:22 pmRNSResult of AGM
2nd Aug 20167:00 amRNSR&D Grant Funding
4th Jul 20168:18 amRNSHolding(s) in Company
1st Jul 201611:48 amRNSHolding(s) in Company
27th Jun 20167:00 amRNSFinal Results
9th Jun 20169:07 amRNSHolding(s) in Company
21st Apr 20167:00 amRNSTrading Update & Notice of Results
8th Feb 20168:22 amRNSHolding(s) in Company
4th Dec 20154:25 pmRNSHolding(s) in Company
3rd Dec 201512:28 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSHalf Yearly Report
26th Oct 20157:00 amRNSTrading Update and Notice of Interim Results
30th Sep 20159:07 amRNSGrant of Options
7th Sep 20151:21 pmRNSResult of AGM
7th Jul 20157:00 amRNSFinal Results
5th Jun 201510:01 amRNSHolding(s) in Company
1st Jun 20157:00 amRNSDevelopment Update - Visitect® CD4 and Allergy
27th Apr 20157:00 amRNSBoard Appointment
15th Apr 20157:00 amRNSTrading update and Notice of Results
1st Dec 201410:37 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.